Zobrazeno 1 - 10
of 1 184
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Publikováno v:
Drug Safety
Introduction The safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy
Autor:
Yongjun Xue, Sekhar Surapaneni, Mark Thomas, Gopal Krishna, Leonidas N Carayannopoulos, Simon Zhou, Mary Liu, Jeanelle Kam, Liangang Liu, Ken Ogasawara, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:369-377
Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The ob
Autor:
Masaji Tani, Shin-ya Morita, Tomohiro Terada, Naoki Yabuta, Daiki Hira, Hiroya Iida, Masatomo Sudou, Satoshi Noda, Akira Andoh, Yoshinori Wakasugi, Takehide Fujimoto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:281-288
Purpose:We aimed to evaluate exposure-toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC).
Methods:In this retrospective, observational study, 28 HCC patien
Methods:In this retrospective, observational study, 28 HCC patien
Autor:
Hiroshi Kawamoto, Naoko Hattori, Akihiro Sato, Tsukiko Higuchi, Masako Nakamoto, Chika Nitani, Toshimi Kimura, Shigehisa Kitano, Toshikazu Ushijima, Hiromi Ono, Junichi Hara, Kenichi Yoshimura, Akinobu Hamada, Tomoaki Taguchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:99-107
Tamibarotene is a synthetic retinoid that inhibits proliferation and induces differentiation of malignant cells by binding to the retinoic acid receptor α/β. Previous in vitro studies have shown that some pediatric solid tumors with retinoic acid r
Autor:
Richard B. Womer, Joseph Gottschalk, Elizabeth Fox, Alexander DeBernardo, Christine Busch, Naomi Balamuth, Blair Segers, Rochelle Bagatell, Frank M. Balis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:807-815
High dose methotrexate (HDMTX) acute kidney injury (AKI) results in prolonged hospitalization and treatment delays. Using a pharmacologically-based approach, HDMTX was administered with standard combination therapy to patients with osteosarcoma; neph
Autor:
Malaz Abutarif, David Jaworowicz, Alexander E. Perl, Jill Fiedler-Kelly, Youngsook Choi, Nigel H. Russell, Siddhartha Ganguly, Alwin Krämer, Ophelia Yin, Mark J. Levis, Samer K. Khaled, Dongwoo Kang, Giovanni Martinelli, Jorge E. Cortes, Elizabeth Ludwig, Hannah Huang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) tre